Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity Samyah Shadid, Michael D Jensen Clinical Gastroenterology and Hepatology Volume 1, Issue 5, Pages 384-387 (September 2003) DOI: 10.1053/S1542-3565(03)00198-8
Figure 1 The mean and SD of the AST and ALT over time during pioglitazone treatment are depicted. The difference between the effect of pioglitazone on AST (P = 0.05) and ALT (P < 0.0001) was significant between NAFLD and previously normal liver function tests. The dashed line represents the top of the normal range. Clinical Gastroenterology and Hepatology 2003 1, 384-387DOI: (10.1053/S1542-3565(03)00198-8)